DEF: Grace Therapeutics Schedules 2025 Annual Meeting, Seeks Shareholder Approval for Directors and Executive Compensation

Grace Therapeutics, Inc. announced its 2025 Annual Meeting of Stockholders to be held virtually on September 12, 2025, seeking approval for director nominees, executive compensation, and auditor ratification.

Summary

• The 2025 Annual Meeting of Stockholders will be held virtually on September 12, 2025, at 8:30 a.m. Eastern Time.
• Stockholders will vote on three key proposals: the election of five director nominees for a one-year term, an advisory vote on the compensation of named executive officers, and the ratification of KPMG LLP as the independent registered public accounting firm for the fiscal year ending March 31, 2026.
• The Board of Directors unanimously recommends voting FOR ALL director nominees and FOR both the executive compensation and auditor ratification proposals.
• Only stockholders of record as of July 18, 2025, are entitled to vote, with 13,828,562 shares of common stock outstanding and eligible to vote.
• The company encourages stockholders to vote by proxy online, by telephone, or by mail prior to the meeting, even if they plan to attend the virtual meeting.
• The company changed its jurisdiction of incorporation from Quebec to British Columbia on October 1, 2024, and subsequently to Delaware on October 7, 2024.
• The Board separated its Governance and Human Resources Committee into a Compensation Committee and a Nominating and Corporate Governance Committee effective November 12, 2024.

Sentiment

Score: 7

Explanation: The filing is a routine proxy statement, generally neutral in sentiment. However, the completion of the Phase 3 STRIVE ON safety trial for GTx-104 meeting expectations and the successful capital raises indicate positive operational and financial progress, leading to a slightly positive sentiment.

Positives

• The Board of Directors unanimously recommends voting FOR all proposals, indicating alignment and confidence in current governance and compensation structures.
• The company maintains an independent Chair of the Board, separating the roles of Board Chair and Chief Executive Officer to reinforce board independence and oversight.
• Robust corporate governance policies are in place, including an Insider Trading Policy, Hedging Policy, and an Incentive Compensation Recovery Policy, promoting compliance and accountability.
• The Audit Committee has determined that Mr. Davis qualifies as an audit committee financial expert, enhancing financial oversight.
• The Compensation Committee engaged an independent compensation consultant, Pearl Meyer & Partners, LLC, to review executive and non-employee director compensation programs, aiming for competitive and aligned compensation.

Negatives

• The Annual Meeting will be held virtually only, which may limit direct in-person engagement for some stockholders.

Risks

• The Board as a whole has responsibility for risk oversight, with committees overseeing specific areas.
• Areas of risk evaluated include research and development, patents, commercial matters, human resources, cybersecurity, funding, regulatory matters, operational risks, financial (accounting, liquidity and tax) matters, legal compliance, compensation, competitive risks, and health, safety, and reputational risks.

Future Outlook

The company anticipates holding its next required vote on the frequency of say-on-pay votes at the 2026 Annual Meeting of Stockholders. A key corporate objective for the fiscal year ended March 31, 2025, was the completion of the Phase 3 STRIVE ON safety trial for the lead product candidate, GTx-104, which met expectations. Future milestones include potential FDA New Drug Application (NDA) acceptance and approval for GTx-104, which is tied to the expiration of certain warrants.

Management Comments

• Prashant Kohli, Chief Executive Officer, stated, 'It is important that your shares be represented at the Annual Meeting regardless of the size of your holdings. Whether or not you plan to attend the Annual Meeting, please provide your proxy by following the instructions described in the Proxy Statement.'

Industry Context

Grace Therapeutics operates within the life science and biopharmaceutical industry, with a focus on product development and drug delivery, including specialty and small molecule drugs for rare and orphan diseases. The company's executive compensation program is designed to be competitive with comparable organizations in this sector, aiming to attract, motivate, and retain high-performing senior executives.

Comparison to Industry Standards

• Executive compensation programs are reviewed to ensure alignment with current market practices and competitiveness with compensation received by executives employed by comparable public life science companies.
• Non-employee director compensation program was established based on advice from an independent compensation consultant, Pearl Meyer, to align with compensation levels of similarly situated public life science companies.

Management Changes

Corporate Governance

Related Party Transactions

• **2025 Private Placement (February 11, 2025):** Shore Pharma LLC (an entity held in a trust for the benefit of immediate family members of Vimal Kavuru, Chair of the Board), ADAR1 Partners, LP, AIGH Investment Partners, LP, and SS Pharma LLC (each a beneficial owner of more than 5% of common stock) participated, resulting in gross proceeds of approximately $5.7 million.
• **2023 Private Placement (September 2023):** Shore Pharma LLC (beneficial owner of 6.9% of common shares outstanding prior to the placement and controlled by Vimal Kavuru at the time) and SS Pharma LLC (beneficial owner of 5.5% of common shares outstanding prior to the placement) participated, resulting in gross proceeds of $2.5 million.

Stakeholder Impact

• **Shareholders:** Will vote on key governance matters, including director elections, executive compensation, and auditor ratification. Their voting power is directly impacted by the 13,828,562 shares outstanding. Participation in private placements by significant shareholders and related parties impacts ownership structure.
• **Employees:** Executive officers' compensation is subject to an advisory vote, and they participate in a 401K plan with a 3% salary contribution. Stock option awards are a significant part of their compensation, aligning their interests with company performance.
• **Management:** Executive officers' compensation is tied to corporate objectives, including the completion of the Phase 3 STRIVE ON safety trial for GTx-104. Their employment agreements include severance provisions.
• **Board of Directors:** The board structure, independence, and committee responsibilities are detailed, impacting their oversight and strategic guidance roles. Director compensation includes cash fees and equity grants.

Next Steps

• Hold the 2025 Annual Meeting of Stockholders virtually on September 12, 2025.
• Elect five director nominees for a one-year term expiring at the 2026 Annual Meeting.
• Conduct an advisory vote on the compensation of named executive officers.
• Ratify the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending March 31, 2026.
• Potentially hold the next required vote on the frequency of say-on-pay votes at the 2026 Annual Meeting of Stockholders.
• Continue efforts towards FDA New Drug Application (NDA) acceptance and approval for GTx-104.

Key Dates

Recommendation

This filing is a routine proxy statement detailing corporate governance matters, executive compensation proposals, and the upcoming annual meeting agenda. It does not contain new financial results or strategic announcements that would typically cause significant share price movement. While it confirms the completion of a Phase 3 trial for GTx-104, this was a corporate objective for the past fiscal year and is not a new clinical data release. The capital raises mentioned are historical events. Therefore, a 'hold' recommendation is appropriate as the filing provides procedural updates rather than new information warranting a change in investment thesis.

Keywords

Proxy Statement, Annual Meeting, Corporate Governance, Executive Compensation, Director Election, Auditor Ratification, SEC Filing, Stockholder Vote, Biopharmaceutical, Life Science, GTx-104